VoxEU Column How to nudge COVID-19 vaccination while respecting autonomous decision making Tomoya Saito Shusaku Sasaki Fumio Ohtake 13 Dec 2021 COVID-19
VoxEU Column Heterogeneous firm-level impact of Covid-19 and the role of vaccine developments in recovery expectations Enrique Moral-Benito 26 Aug 2021 COVID-19 Productivity and Innovation
Discussion paper DP16324 Could Vaccine Dose Stretching Reduce COVID-19 Deaths? Witold Więcek Amrita Ahuja Michael Kremer Alexandre Simoes Gomes Junior Christopher Snyder Alex Tabarrok Brandon Tan 3 Jul 2021 Development Economics
VoxEU Column From tragedy to hesitancy: How public health failures boosted COVID-19 vaccine scepticism Hans-Joachim Voth Bruno Caprettini Dominic Rohner Geraldine Blanchard-Rohner 1 Jun 2021 Health Economics COVID-19
Discussion paper DP15980 The welfare cost of vaccine misallocation, delays and nationalism Christian Gollier 30 Mar 2021 Public Economics
VoxEU Column The value of a vaccine to end COVID-19 is worth between 5% and 15% of wealth Steven Zheng Timothy Johnson Suresh Sundaresan Viral Acharya 19 Jan 2021 COVID-19 Financial Markets
VoxEU Column Why prudent people might avoid vaccinations Thomas Mayrhofer Hendrik Schmitz Leonard Goebel 12 Dec 2020 COVID-19
Discussion paper DP15558 The Value of a Cure: An Asset Pricing Perspective Viral Acharya Timothy Johnson Suresh Sundaresan Steven Zheng 11 Dec 2020 Financial Economics Macroeconomics and Growth Public Economics G12 D5 I1 Q54
VoxEU Column Vaccine challenges Barry Eichengreen Orkun Saka Cevat Giray Aksoy 16 Nov 2020 COVID-19 Health Economics
Discussion paper DP15433 Optimal Subsidies for Prevention of Infectious Disease Michael Kremer Heidi Williams Christopher Snyder Matthew Goodkin-Gold 6 Nov 2020 Development Economics Industrial Organization O31 L11 I18 D42
VoxEU Column A vaccination policy for green zones Bary Pradelski Miquel Oliu-Barton 2 Oct 2020 COVID-19
VoxEU Column How to strengthen European industries’ leadership in vaccine research and innovation Michel Goldman Sofia Amaral-Garcia Mathias Dewatripont Philippe Aghion 1 Sep 2020 COVID-19 EU policies Health Economics
